Therapeutic Effects of Lifei Decoction in a Murine Model of COPD Induced by LPS and Cigarette Smoke

References

• Blanco I, Diego I, Bueno P, Casas-Maldonado F, Miravitlles M. Geographic distribution of COPD prevalence in the world displayed by geographic information system maps. Eur Respir J. 2019;54. doi:10.1183/13993003.00610-2019
   PubMed Web of Science ®Google Scholar
• Momtazmanesh S, Moghaddam SS, Ghamari S-H. Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the global burden of disease study 2019. EClinicalMedicine. 2023;59:101936. doi:10.1016/j.eclinm.2023.101936
   PubMedGoogle Scholar
• Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet. 2022;399:2227–2242. doi:10.1016/S0140-6736(22)00470-6
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Criner GJ, Papi A, et al. Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2021;203:24–36. doi:10.1164/rccm.202009-3533SO
   PubMed Web of Science ®Google Scholar
• Wang L, Cai Y, Garssen J, Henricks PAJ, Folkerts G, Braber S. The bidirectional gut-lung axis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2023;207:1145–1160. doi:10.1164/rccm.202206-1066TR
   PubMedGoogle Scholar
• Park EM, Chelvanambi M, Bhutiani N, Kroemer G, Zitvogel L, Wargo JA. Targeting the gut and tumor microbiota in cancer. Nat Med. 2022;28:690–703. doi:10.1038/s41591-022-01779-2
   PubMed Web of Science ®Google Scholar
• Bowerman KL, Rehman SF, Vaughan A, et al. Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease. Nat Commun. 2020;11:5886. doi:10.1038/s41467-020-19701-0
   PubMed Web of Science ®Google Scholar
• Lai H-C, Lin T-L, Chen T-W, et al. Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory parabacteroides goldsteinii lipopolysaccharide. Gut. 2022;71:309–321. doi:10.1136/gutjnl-2020-322599
   PubMed Web of Science ®Google Scholar
• Wang J, Ren C, Jin L, Batu W. Seabuckthorn Wuwei Pulvis attenuates chronic obstructive pulmonary disease in rat through gut microbiota-short chain fatty acids axis. J Ethnopharmacol. 2023;314:116591. doi:10.1016/j.jep.2023.116591
   PubMed Web of Science ®Google Scholar
• Li J, Xie Y, Zhao P, et al. A Chinese herbal formula ameliorates COPD by inhibiting the inflammatory response via downregulation of p65, JNK, and p38. Phytomedicine. 2021;83:153475. doi:10.1016/j.phymed.2021.153475
   PubMed Web of Science ®Google Scholar
• Chen L, Li L, Zou S, Liao Q, Lv B. Tong‑fu‑li‑fei decoction attenuates immunosuppression to protect the intestinal‑mucosal barrier in sepsis by inhibiting the PD‑1/PD‑L1 signaling pathway. Mol Med Rep. 2021;24. doi:10.3892/mmr.2021.12480
   Web of Science ®Google Scholar
• Chen L, Li L, Han Y, Lv B, Zou S, Yu Q. Tong-fu-li-fei decoction exerts a protective effect on intestinal barrier of sepsis in rats through upregulating ZO-1/occludin/claudin-1 expression. J Pharmacol Sci. 2020;143:89–96. doi:10.1016/j.jphs.2020.02.009
   PubMed Web of Science ®Google Scholar
• Li D, Sun D, Yuan L, et al. Sodium tanshinone IIA sulfonate protects against acute exacerbation of cigarette smoke-induced chronic obstructive pulmonary disease in mice. Int Immunopharmacol. 2020;81:106261. doi:10.1016/j.intimp.2020.106261
   PubMed Web of Science ®Google Scholar
• Chunhua M, Long H, Zhu W, et al. Betulin inhibited cigarette smoke-induced COPD in mice. Biomed Pharmacother. 2017;85:679–686. doi:10.1016/j.biopha.2016.11.079
   PubMed Web of Science ®Google Scholar
• Lakshman Kumar P, Wilson AC, Rocco A, et al. Genetic variation in genes regulating skeletal muscle regeneration and tissue remodelling associated with weight loss in chronic obstructive pulmonary disease. J Cachexia, Sarcopenia Muscle. 2021;12:1803–1817. doi:10.1002/jcsm.12782
   PubMed Web of Science ®Google Scholar
• Song W, Yue Y, Zhang Q. Imbalance of gut microbiota is involved in the development of chronic obstructive pulmonary disease: a review. Biomed Pharmacother. 2023;165:115150. doi:10.1016/j.biopha.2023.115150
   PubMed Web of Science ®Google Scholar
• Bhatt SP, O’Connor GT. Screening for chronic obstructive pulmonary disease: challenges and opportunities. JAMA. 2022;327:1768–1770. doi:10.1001/jama.2022.3823
   PubMed Web of Science ®Google Scholar
• Tuder RM, Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest. 2012;122:2749–2755. doi:10.1172/JCI60324
   PubMed Web of Science ®Google Scholar
• Lee EH, Shin MH, Gi M, et al. Inhibition of pendrin by a small molecule reduces lipopolysaccharide-induced acute lung injury. Theranostics. 2020;10:9913–9922. doi:10.7150/thno.46417
   PubMed Web of Science ®Google Scholar
• Liu C-H, Chen Z, Chen K, et al. Lipopolysaccharide-mediated chronic inflammation promotes tobacco carcinogen-induced lung cancer and determines the efficacy of immunotherapy. Cancer Res. 2021;81:144–157. doi:10.1158/0008-5472.CAN-20-1994
   PubMed Web of Science ®Google Scholar
• Zhou R, Luo F, Lei H, et al. Liujunzi Tang, a famous traditional Chinese medicine, ameliorates cigarette smoke-induced mouse model of COPD. J Ethnopharmacol. 2016;193:643–651. doi:10.1016/j.jep.2016.09.036
   PubMed Web of Science ®Google Scholar
• Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. Eur Respir J. 2019;54. doi:10.1183/13993003.00651-2019
   Web of Science ®Google Scholar
• Wang Y, Xu J, Meng Y, Adcock IM, Yao X. Role of inflammatory cells in airway remodeling in COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:3341–3348. doi:10.2147/COPD.S176122
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003;22:672–688. doi:10.1183/09031936.03.00040703
   PubMed Web of Science ®Google Scholar
• Baker RG, Hayden MS, Ghosh S. NF-κB, inflammation, and metabolic disease. Cell Metab. 2011;13:11–22. doi:10.1016/j.cmet.2010.12.008
   PubMed Web of Science ®Google Scholar
• Fan Y, Zhang Z, Yao C, et al. Amurensin H, a derivative from resveratrol, ameliorates lipopolysaccharide/cigarette smoke-induced airway inflammation by blocking the syk/nf-κb pathway. Front Pharmacol. 2019;10:1157. doi:10.3389/fphar.2019.01157
   PubMed Web of Science ®Google Scholar
• Brun CE, Rudnicki MA. GDF11 and the mythical fountain of youth. Cell Metab. 2015;22:54–56. doi:10.1016/j.cmet.2015.05.009
   PubMed Web of Science ®Google Scholar
• Król W, Machelak W, Zielińska M. GDF11 as a friend or an enemy in the cancer biology? Biochim Biophys Acta Rev Cancer. 2023;1878:188944. doi:10.1016/j.bbcan.2023.188944
   PubMed Web of Science ®Google Scholar
• Onodera K, Sugiura H, Yamada M, et al. Decrease in an anti-ageing factor, growth differentiation factor 11, in chronic obstructive pulmonary disease. Thorax. 2017;72:893–904. doi:10.1136/thoraxjnl-2016-209352
   PubMed Web of Science ®Google Scholar
• Tang F, Ling C, Liu J. Reduced expression of growth differentiation factor 11 promoted the progression of chronic obstructive pulmonary disease by activating the AKT signaling pathway. Biomed Pharmacother. 2018;103:691–698. doi:10.1016/j.biopha.2018.04.091
   PubMed Web of Science ®Google Scholar
• Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. Nature. 2016;535:65–74. doi:10.1038/nature18847
   PubMed Web of Science ®Google Scholar
• Lynch SV, Pedersen O, Phimister EG. The human intestinal microbiome in health and disease. N Engl J Med. 2016;375:2369–2379. doi:10.1056/NEJMra1600266
   PubMed Web of Science ®Google Scholar
• Caballero S, Pamer EG. Microbiota-mediated inflammation and antimicrobial defense in the intestine. Annu Rev Immunol. 2015;33:227–256. doi:10.1146/annurev-immunol-032713-120238
   PubMed Web of Science ®Google Scholar
• Budden KF, Gellatly SL, Wood DLA, et al. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol. 2017;15:55–63. doi:10.1038/nrmicro.2016.142
   PubMed Web of Science ®Google Scholar
• Qu L, Cheng Q, Wang Y, Mu H, Zhang Y. COPD and gut-lung axis: how microbiota and host inflammasome influence COPD and related therapeutics. Front Microbiol. 2022;13:868086. doi:10.3389/fmicb.2022.868086
   PubMed Web of Science ®Google Scholar
• Vutcovici M, Bitton A, Ernst P, Kezouh A, Suissa S, Brassard P. Inflammatory bowel disease and risk of mortality in COPD. Eur Respir J. 2016;47:1357–2015. doi:10.1183/13993003.01945-2015
   PubMed Web of Science ®Google Scholar
• Rodriguez-Roisin R, Bartolome SD, Huchon G, Krowka MJ. Inflammatory bowel diseases, chronic liver diseases and the lung. Eur Respir J. 2016;47:638–2015. doi:10.1183/13993003.00647-2015
   PubMed Web of Science ®Google Scholar